Evidence map›Paper›PMID 41673716›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Lysine Targeting Group-Transfer Chimeras for Proximity Induction.

Sameek Singh, Kien Tran, Endri Karaj, Basudeb Mondal, Wenzhi Tian, Surached Siriwongsup, Shaimaa H Sindi, Uttam Dhawa, Kaushik Pal, Veronika M Shoba and 7 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. A Scalable Design for Proximity-Inducing Molecules.bioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sameek Singh *Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.ORCID 0000-0001-5546-6754
Kien Tran *Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.ORCID 0000-0002-2018-3591
Endri Karaj *Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.ORCID 0000-0002-2393-9278
Basudeb Mondal *Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.ORCID 0000-0002-6676-9846
Wenzhi Tian *Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.ORCID 0009-0001-7839-587X
Surached SiriwongsupChemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.ORCID 0000-0002-1176-9515
Shaimaa H SindiChemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.ORCID 0000-0003-4319-0441
Uttam DhawaChemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.ORCID 0000-0003-1161-6700
Kaushik PalChemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.ORCID 0000-0001-8638-2334
Veronika M ShobaChemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.ORCID 0000-0003-0402-7414
Sunny ShiChemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Anna LianDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Jody MouDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Myeonghoon HanChemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Prashant SinghChemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.ORCID 0009-0002-8893-2373
Nicholas F PolizziDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.ORCID 0000-0002-1779-8907
Amit ChoudharyChemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.ORCID 0000-0002-8437-0150

Funding

Development of platforms for beta cell-specific delivery and ligand discoveryU01DK137242 · NIDDK · BROAD INSTITUTE, INC. · PI Amit Choudhary, ROHIT N. KULKARNI · 2023 to 2026
$3.9M
Interrogating the ubiquitin pathway to understand and treat cytokine-induced beta-cell death in type 1 diabetesR01DK129464 · NIDDK · BROAD INSTITUTE, INC. · PI CHOUDHARY, AMIT, KULKARNI, ROHIT N. · 2021 to 2024
$2.1M
Chemical approaches for precision genome editingR01GM137606 · NIGMS · BROAD INSTITUTE, INC. · PI CHOUDHARY, AMIT · 2021 to 2024
$1.5M
Development of synthetic gene drives using small moleculesR01GM132825 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI AKBARI, OMAR SULTAN, CHOUDHARY, AMIT · 2019 to 2022
$1.4M
De novo design of small-molecule-binding proteinsR00GM135519 · NIGMS · DANA-FARBER CANCER INST · PI POLIZZI, NICHOLAS · 2022 to 2024
$747k
Development of phosphorylation editing chimeras using kinase inhibitorsR21AI178690 · NIAID · BROAD INSTITUTE, INC. · PI CHOUDHARY, AMIT · 2024 to 2025
$462k
Development of phosphorylation-inducing chimeric small moleculesR21AI154099 · NIAID · BROAD INSTITUTE, INC. · PI CHOUDHARY, AMIT · 2020 to 2021
$440k
Induced-Proximity Platform to Control Cellular Signaling and ProteostasisK99GM159057 · NIGMS · BROAD INSTITUTE, INC. · PI KARAJ, ENDRI · 2025 to 2025
$118k
Defense Sciences Office, DARPA HR00112120010Dubai Harvard Foundation for Medical ResearchNIAID NIH HHS R21 AI154099NIAID NIH HHS R21 AI178690NIDDK NIH HHS R01 DK129464NIDDK NIH HHS U01 DK137242NIGMS NIH HHS K99 GM159057NIGMS NIH HHS R00 GM135519NIGMS NIH HHS R01 GM132825NIGMS NIH HHS R01 GM137606NIH HHS K99GM159057NIH HHS R00GM135519NIH HHS R01DK129464NIH HHS R01GM132825NIH HHS R01GM137606NIH HHS R21AI154099NIH HHS U01DK137242
6 · The paper itself

Abstract

Nature employs post-translational modifications (PTMs) to induce proximity between proteins by engendering new interactions. Furthermore, we find that protein ligands are invariably proximal to a lysine. Inspired by these two observations, we developed group-transfer chimeras (GRCs) that append a moiety-of-interest to the lysine side chain. GRCs employ a protein's ligand and a handle with a transferase-type reactivity to modify the proximal lysine. Contemporary lysine-targeting group-transfer handles were incompatible with GRCs due to their hydrolytic instability, large size, high reactivity, and synthetic incompatibility with diverse ligands. Accordingly, we developed an N-(sulfonyl)-N-(trifluoroethyl)-ethanamide (SuFA) handle that is stable, small, and exhibits tunable reactivity and synthetic compatibility with diverse ligands and proteins. Using GRCs that group-transfer binders of tags (e.g., HaloTag, FKBP) onto proteins overexpressed in cancer cells, we displayed these binders on the surface of the cancer cell. With a universal T cell engager (UniTE) that binds to the displayed ligands and T cells, these GRCs induced proximity between cancer cells and cytotoxic T cells, leading to the latter's activation. We envision the GRC platform to find utility in basic research and biomedicine.

Indexed as

LysineProteinsHumansLigandsProtein Processing, Post-TranslationalLigandsLysineProteinsGroup transferImmunotherapyLysineProtein modificationsProteomics

Identifiers

PMID41673716
PMCPMC13410498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.